Navigation Links
Ceregene Reports New Findings Regarding How Parkinson's Brains Respond to Neurotrophic Factors
Date:2/15/2011

further support the safety and clinical benefit of CERE-120.

For more information, see PDTrials.org or log onto Ceregene's web site (www.Ceregene.com).

About Parkinson's Disease

Parkinson's disease is a progressive movement disorder that affects a million people in the United States.  Its main symptoms, stiffness, tremors and slowed movements and gait, are caused by a loss of dopamine-containing nerve cells in the substantia nigra, which project their axons to the putamen.  Dopamine is a neurotransmitter involved in controlling movement and coordination, so Parkinson's patients exhibit a progressive inability to initiate and control physical movements.  There is currently no treatment that can reverse the degeneration of these neurons, let alone cure Parkinson's disease.

About Ceregene

Ceregene, Inc. is a San Diego-based biotechnology company focused on the delivery of nervous system growth (neurotrophic) factors for the treatment of neurodegenerative and retinal disorders using gene delivery.  Ceregene's clinical programs include CERE-110, an AAV2 based vector expressing nerve growth factor (NGF) currently in a multi-center, controlled Phase 2 study for the treatment of Alzheimer's disease (in collaboration with the ADCS), and CERE-120 (AAV2-Neurturin) for Parkinson's disease.  Ceregene was launched in January 2001.  The company's investors include Alta Partners, MPM Capital, Hamilton BioVentures, Investor Growth Capital, California Technology Partners and BioSante Pharmaceuticals (Nasdaq: BPAX).


'/>"/>
SOURCE Ceregene, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Ceregene Receives Additional Grant From Michael J. Fox Foundation to Expand Long-Term Testing of CERE-120 Patients
2. Ceregene Announces Clinical Data From Phase 2 Clinical Trial of CERE-120 for Parkinsons Disease
3. SeraCare Reports First Quarter Fiscal Year 2011 Results
4. Neurocrine Biosciences Reports Fourth Quarter and Year End 2010 Results
5. YM BioSciences Reports Fiscal Second Quarter 2011 Operational and Financial Results
6. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Results
7. ERT Reports Fourth Quarter and Full Year 2010 Operating Results on March 1, 2011
8. Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be
9. Pharmacyclics Reports Recent Developments and Financial Results for Fiscal Second Quarter 2011
10. Codexis Reports Fourth Quarter and Full Year 2010 Results
11. Sangamo BioSciences Reports Fourth Quarter and Full Year 2010 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... ... ... A new host-based therapy for Ebola, anthrax and other ... and its collaborators. The discovery has the potential to speed to market treatments ... by Scientific Reports, an open access research journal from the publishers of Nature. ...
(Date:8/31/2015)... 2015 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the ... are for air emission abatement projects in North ... large order for a municipality in the Southern ... competitor,s system that failed to meet the customer,s requirements. This demonstrates ... Derek S. Webb , President and Chief Executive Officer.  ...
(Date:8/31/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/53wxp3/israel_biomedical ) ... Sensors Market - Growth, Trends & Forecasts (2014-2020)" ... Biomedical Sensors market is estimated at $0.19 billion by ... 2014-2020 The near future will bring biomedical ... each individual. These sensors can be set to trigger ...
(Date:8/31/2015)... -- US-Australian drug discovery company, Novogen Limited (ASX: NRT; ... scientific review has identified high value opportunities for ... patient need. Novogen is moving as quickly as ... entering into Phase 1 clinical trials with our ... Officer, Iain Ross , said that following ...
Breaking Biology Technology:Scientists Discover New Use for an Old Therapy Inhibiting Deadly Pathogens Including Ebola and Anthrax 2Scientists Discover New Use for an Old Therapy Inhibiting Deadly Pathogens Including Ebola and Anthrax 3Scientists Discover New Use for an Old Therapy Inhibiting Deadly Pathogens Including Ebola and Anthrax 4Israel Biomedical Sensors Market 2015 - Growth, Trends & Forecasts to 2020 2Novogen Announces The Outcome Of A Comprehensive Science Review 2Novogen Announces The Outcome Of A Comprehensive Science Review 3Novogen Announces The Outcome Of A Comprehensive Science Review 4Novogen Announces The Outcome Of A Comprehensive Science Review 5Novogen Announces The Outcome Of A Comprehensive Science Review 6
... dream of competing together to race the fastest cars they ... group of 20 engineers, scientists and technicians from Ohio State ... is to win the $1 million dollar grand prize awarded ... , ,The Defense Advanced Research Projects Agency (DARPA) has ...
... Wis. -- Fiserv Inc., a provider ... Management, a portfolio management and investment accounting solution. ... trade execution, accounting, international settlement support and regulatory ... handle several accounting bases and closing dates and ...
... and community development specialist, presented a hopeful outlook for ... on Economic Development . Abstaining from morbid statistics and ... businesses in Wisconsin. , ,Wisconsin manufacturing suffered very little ... He cited that Wisconsin saw only a 9.1 percent ...
Cached Biology Technology:Oshkosh Truck Teams with OSU to Compete in DARPA Million Dollar Tech Derby 2Oshkosh Truck Teams with OSU to Compete in DARPA Million Dollar Tech Derby 3Optimistic Outlook For Manufacturing 2
(Date:8/5/2015)... According to a new market ... Services, Vertical (BFSI, Airport, IT & Telecom, Utilities, Education, ... to 2020", published by MarketsandMarkets, defines and segments the ... segments. The global PIAM Market is estimated to grow ... 2019, at a CAGR of 14.9 % from 2014 ...
(Date:8/5/2015)... Calif. , Aug. 5, 2015 The ... continuous growth in applications, penetration into newer sectors, and ... year. The global biosensors space has seen the entry ... the market so far. (Photo - ... & Sullivan, Analysis of the Global Biosensors Market ...
(Date:8/4/2015)... ALBANY, N.Y., Aug. 4, 2015  AMRI (NASDAQ: AMRI ) ... June 30, 2015. Highlights: , Second quarter ... increase from 2014 , Adjusted contract margins of ... EPS of $0.22, including a $0.05 decrease in EPS from royalties ... of $16 million "We are very pleased to ...
Breaking Biology News(10 mins):Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4AMRI Announces Second Quarter 2015 Results 2AMRI Announces Second Quarter 2015 Results 3AMRI Announces Second Quarter 2015 Results 4AMRI Announces Second Quarter 2015 Results 5AMRI Announces Second Quarter 2015 Results 6AMRI Announces Second Quarter 2015 Results 7AMRI Announces Second Quarter 2015 Results 8AMRI Announces Second Quarter 2015 Results 9AMRI Announces Second Quarter 2015 Results 10AMRI Announces Second Quarter 2015 Results 11AMRI Announces Second Quarter 2015 Results 12AMRI Announces Second Quarter 2015 Results 13AMRI Announces Second Quarter 2015 Results 14AMRI Announces Second Quarter 2015 Results 15AMRI Announces Second Quarter 2015 Results 16AMRI Announces Second Quarter 2015 Results 17AMRI Announces Second Quarter 2015 Results 18AMRI Announces Second Quarter 2015 Results 19AMRI Announces Second Quarter 2015 Results 20AMRI Announces Second Quarter 2015 Results 21AMRI Announces Second Quarter 2015 Results 22AMRI Announces Second Quarter 2015 Results 23AMRI Announces Second Quarter 2015 Results 24
... expensive DNA sequencing strategy, scientists have discovered genetic alterations ... rare disorder that causes multiple birth defects and mental ... new approach sequences just the exome, the 1-2 percent ... Kabuki syndrome, which has an estimated incidence of ...
... BIO-key International, Inc. (OTC Bulletin Board: http://photos.prnewswire.com/prnh/20050509/BIOKEYLOGO ) (Logo: ... What: , BIO-key International, Inc. Second Quarter 2010 Conference ... Thursday, July 29, 2010 - 10:00 a.m. Eastern Time , ... phone by dialing 800-860-2442 and asking for the BIO-key call at least ...
... Aug. 11 Chip Supply, Inc., a global provider ... to host a visit yesterday by U.S. Senator George ... is a co-sponsor of the Export Promotion Act (bipartisan ... business sector), met with Chip Supply to review, firsthand, ...
Cached Biology News:Discovered gene causes Kabuki syndrome 2Discovered gene causes Kabuki syndrome 3BIO-key® Announces Second Quarter 2010 Earnings Release and Conference Call Schedule 2BIO-key® Announces Second Quarter 2010 Earnings Release and Conference Call Schedule 3Chip Supply Hosts Visit by U.S. Senator George LeMieux 2
... Species Tissue Array (MSTA) slides were designed to ... tissues from multiple species. Tissue slices from ... slide which can then be treated as a ... in situ hybridization. This format ...
... is used on Macintosh operating systems ... any DNA sequence up to 3,200 ... of primers and GC clamps for ... electrophoresis (DGGE), constant denaturing gel electrophoresis ...
... To score SNPs, Polymorphic uses proven, validated ... in DNA analysis. We use high throughput ... be confirmed by sequencing in both directions. ... sequence context information, further confirming the location ...
... PowerPac basic power supply are used for submerged ... gels. This Model 192 cell includes a buffer ... tray with fluorescent ruler, and a gel caster. ... V, provides output of 10-300 V, 4-400 mA, ...
Biology Products: